title: Bedaquiline - The first ATP synthase inhibitor against multi drug resistant tuberculosis.
abstract: Increasing incidence of MDR-TB, long duration of treatment and co-infection with HIV are the significant problems in achieving the eradication of tuberculosis. Bedaquiline is an anti-tuberculosis drug with unique mechanism of action. It selectively inhibits the mycobacterial energy metabolism i.e. ATP synthesis and found to be effective against all states of Mycobacterium tuberculosis like active, dormant, replicating, non-replicating, intracellular and extracellular. Preclinical studies have shown the efficacy of bedaquiline in terms of reduction in bacterial load and treatment duration. Phase II clinical studies have established the safety, tolerability and earlier sputum conversion time in patients with MDR-TB. In 2012 FDA approved bedaquiline for treatment of MDR-TB and XDR-TB.
authors.affiliation: Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry 605006, India.
authors.forename: Mageshwaran
authors.initials: M
authors.lastname: Lakshmanan
authors.affiliation: Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry 605006, India.
authors.forename: Alphienes Stanley
authors.initials: AS
authors.lastname: Xavier
keywords: ATP synthase inhibitor; Bedaquiline; MDR-TB; Tuberculosis; XDR-TB